EP0858340A4 - Traitement combine du diabete et de l'obesite - Google Patents

Traitement combine du diabete et de l'obesite

Info

Publication number
EP0858340A4
EP0858340A4 EP96937097A EP96937097A EP0858340A4 EP 0858340 A4 EP0858340 A4 EP 0858340A4 EP 96937097 A EP96937097 A EP 96937097A EP 96937097 A EP96937097 A EP 96937097A EP 0858340 A4 EP0858340 A4 EP 0858340A4
Authority
EP
European Patent Office
Prior art keywords
obesity
diabetes
treatment
combination therapy
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96937097A
Other languages
German (de)
English (en)
Other versions
EP0858340A1 (fr
Inventor
Roy G Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603724.7A external-priority patent/GB9603724D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0858340A1 publication Critical patent/EP0858340A1/fr
Publication of EP0858340A4 publication Critical patent/EP0858340A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP96937097A 1995-11-01 1996-10-31 Traitement combine du diabete et de l'obesite Withdrawn EP0858340A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US713895P 1995-11-01 1995-11-01
US7138P 1995-11-01
GB9603724 1996-02-22
GBGB9603724.7A GB9603724D0 (en) 1996-02-22 1996-02-22 Combinatyion therapy for the treatment of diabebes and obesity
PCT/US1996/017444 WO1997016189A1 (fr) 1995-11-01 1996-10-31 Traitement combine du diabete et de l'obesite

Publications (2)

Publication Number Publication Date
EP0858340A1 EP0858340A1 (fr) 1998-08-19
EP0858340A4 true EP0858340A4 (fr) 1999-12-29

Family

ID=26308780

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96937097A Withdrawn EP0858340A4 (fr) 1995-11-01 1996-10-31 Traitement combine du diabete et de l'obesite

Country Status (4)

Country Link
EP (1) EP0858340A4 (fr)
JP (1) JPH11515027A (fr)
AU (1) AU7484596A (fr)
WO (1) WO1997016189A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
WO1997026011A1 (fr) * 1996-01-19 1997-07-24 Eli Lilly And Company Formulations de proteine de l'obesite
CA2263826A1 (fr) * 1996-08-30 1998-03-05 Amgen Inc. Methodes pour accroitre la sensibilite d'un individu a la proteine ob par accroissement de l'affinite du recepteur de la proteine ob
JP2002516605A (ja) * 1996-10-31 2002-06-04 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のための併用療法
EP0920864A1 (fr) * 1997-12-03 1999-06-09 Pfizer Products Inc. Thérapie de combinaison comprenant un beta-3 agoniste spécifique et un agent anorexigéne
US6515134B1 (en) * 1999-02-16 2003-02-04 Kaneka Corporation Substituted acetylpridine derivatives and process for the preparation of intermediates for optically active beta-3 agonist by the use of the same
JP2004331500A (ja) * 2001-02-16 2004-11-25 Dainippon Pharmaceut Co Ltd 血中濃度制御製剤
JPWO2003033468A1 (ja) * 2001-10-17 2005-02-03 株式会社カネカ （Ｓ）−α−ハロメチルピリジンメタノール誘導体の製造方法
EP1496838B1 (fr) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Amides substitues
GB0718415D0 (en) 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611003A1 (fr) * 1993-02-09 1994-08-17 Merck & Co. Inc. Phénylsulfonamides substitués comme B3-agonistes selectives pour le traitement du diabète et de l'obésité
WO1995029159A1 (fr) * 1994-04-26 1995-11-02 Merck & Co., Inc. SULFAMIDES SUBSTITUES UTILISES COMME AGONISTES SELECTIFS VIS-A-VIS DES RECEPTEURS β3-ADRENERGIQUES, POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE
EP0920864A1 (fr) * 1997-12-03 1999-06-09 Pfizer Products Inc. Thérapie de combinaison comprenant un beta-3 agoniste spécifique et un agent anorexigéne

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611003A1 (fr) * 1993-02-09 1994-08-17 Merck & Co. Inc. Phénylsulfonamides substitués comme B3-agonistes selectives pour le traitement du diabète et de l'obésité
WO1995029159A1 (fr) * 1994-04-26 1995-11-02 Merck & Co., Inc. SULFAMIDES SUBSTITUES UTILISES COMME AGONISTES SELECTIFS VIS-A-VIS DES RECEPTEURS β3-ADRENERGIQUES, POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE
EP0920864A1 (fr) * 1997-12-03 1999-06-09 Pfizer Products Inc. Thérapie de combinaison comprenant un beta-3 agoniste spécifique et un agent anorexigéne

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9716189A1 *

Also Published As

Publication number Publication date
WO1997016189A1 (fr) 1997-05-09
AU7484596A (en) 1997-05-22
JPH11515027A (ja) 1999-12-21
EP0858340A1 (fr) 1998-08-19

Similar Documents

Publication Publication Date Title
GB9619331D0 (en) Selective ›3 agonists for the treatment of diabetes and obesity
AU7772794A (en) Treatment of obesity
HUP9901089A3 (en) Medical splint
GB9618934D0 (en) Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
EP0832204A4 (fr) Traitement de l'insulinoresistance
GB9808936D0 (en) Combination therapy for the prevention and treatment of osteoporosis
EP0858340A4 (fr) Traitement combine du diabete et de l'obesite
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
EP0969852A4 (fr) Therapie par combinaison d'agents pour le traitement du diabete et de l'obesite
GB9614578D0 (en) Medical treatment
GB9521725D0 (en) Medical treatment
EP0724842A3 (fr) Préparation pour le traitement de l'obésité
GB9711042D0 (en) Combination therapy for the treatment of diabetes and obesity
GB9526264D0 (en) Medical treatment
GB9603724D0 (en) Combinatyion therapy for the treatment of diabebes and obesity
ZA976333B (en) Treatment of obesity
GB9618290D0 (en) Treatment of diabetes
GB2304046B (en) Diabetes therapy
ZA951440B (en) Novel opiold peptides for the treatment of pain and use thereof
GB2307858B (en) Medical treatment
AUPM615094A0 (en) Methods for the prophylactic and therapeutic treatment of diabetes and prediabetic conditions
GB9520496D0 (en) Treatment of medical conditions
GB9520494D0 (en) Treatment of medical conditions
GB9520495D0 (en) Treatment of medical conditions
IL114961A0 (en) Apparatus for medical treatment and massage

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991115

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 6A 61K 31/44 A, 6A 61K 38/18 B, 6A 61K 38/17 B, 6A 61K 38/22 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010501